You are here
P&T September 2016
Escalating drug prices have seeded interest in value-based purchasing, but confusion and controversy have slowed the Centers for Medicare and Medicaid Services, state agencies, and private insurers from pursuing the potential savings.
As researchers devise ever-more-costly therapies and P&T committees try to balance innovation and affordability, managed care experts warn that the struggle to pay the bills could threaten the sustainability of the nation’s inefficient health care system.
Telehealth is becoming mainstream in the U.S., as more consumers, employers, hospital systems, and even insurers adopt the technology. The authors explore the challenges of regulation, reimbursement, and licensing as the modality evolves.
Dr. White, known worldwide as an expert in the use of 24-hour ambulatory blood pressure monitoring (ABPM), discusses hypertension, the importance of accurate measurement, and the utility of ABPM for effective diagnoses and treatment.
We present sessions on the latest trials and treatments for colorectal cancer from the ESMO World Congress and report on new developments in diagnostics and therapy presented at the European Post-Chicago Melanoma/Skin Cancer Meeting.
We report on new developments in diagnostics and therapy presented at the European Post-Chicago Melanoma/Skin Cancer Meeting.
Improve staff training with vendor partnerships
Congress set to tackle biosimilar naming debate
Approvals, new indications, regulatory activities, and more
Cabozantinib (Cabometyx) for advanced renal cell carcinoma; glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) for chronic obstructive pulmonary disease; and ephedrine sulfate (Akovaz) for hypotension during anesthesia
Aripiprazole lauroxil (Aristada) for the treatment of schizophrenia